BioNTech (BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for BNT316/ONC-392 in the ...

Bladder cancer is a relatively small indication for Trodelvy, representing less than 10% of the drug’s sales, Gilead’s CFO ...

Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung ...

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...

Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in ...

Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...

Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...

Jazz Pharmaceuticals (JAZZ) stock gains as lung cancer drug Zepzelca with Roche's (RHHBY) Tecentriq hits main goal in Phase 3 ...

This week sees new and notable appointments at Royal London Ireland, Ipsen, Suir Engineering, Vantiva, Avacta and Nokia ...

Discover a breakthrough imaging technique aimed at improving treatment outcomes for patients with locally advanced ...